Treasury Stock


Status re Novo Nordisk's holding of its own shares (31 March 2008)

In continuation of the company's announcement dated 31 January 2007
concerning a planned share repurchase programme, and pursuant to
Section 204.25 of the New York Stock Exchange Listed Company Manual,
this is to report that Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates on 31 March 2008 owned 27,018,090 of its own
B shares of DKK 1, corresponding to a total nominal value of DKK
27.018.090 or 4.18% of the total share capital. Hereof the
wholly-owned affiliates owned 4,000 B shares of DKK 1, corresponding
to a total nominal value of DKK 4,000 or 0.001% of the total share
capital.

In the first quarter of 2008 a total of 2,057,907 B shares were
repurchased, and 854,947 B shares were disposed of to employees in
connection with employee incentive programmes.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,000
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
For further information please contact:


Media:                 Investors:

Outside North America: Outside North America:
Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Hans Rommer
                       Tel: (+45) 4442 4765
                       hrmm@novonordisik.com

In North America:      In North America:
Sean Clements          Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com   cqfr@novonordisk.com


Stock Exchange Announcement no 19 / 2008